BIO3 RES SRL has a total of 14 patent applications. Its first patent ever was published in 2001. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and Australia. Its main competitors in its focus markets pharmaceuticals and biotechnology are TRANSLATIONAL SCIENCES INC, DIAPHARM LTD and SZETO HAZEL H.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 5 | |
#2 | United States | 4 | |
#3 | Australia | 1 | |
#4 | Hong Kong | 1 | |
#5 | Italy | 1 | |
#6 | Republic of Korea | 1 | |
#7 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Bianchi Marco E | 7 |
#2 | Degryse Bernard | 4 |
#3 | Bonaldi Tiziana | 4 |
#4 | Santangelo Francesco | 4 |
#5 | Pilato Francesco Paolo | 4 |
#6 | Scaffidi Paola | 4 |
#7 | Mueller Susanne | 4 |
#8 | Nigro Vincenzo | 3 |
#9 | Palumbo Roberta | 1 |
#10 | Porto Annalisa | 1 |
Publication | Filing date | Title |
---|---|---|
MX2008012974A | Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis. | |
WO2006077614A1 | Hmgb1 inhibitors and antagonists for the inhibition of atherosclerosis pathogenesis and development | |
AU2002217426A1 | Double buffer system for polymerase chain reaction buffers | |
WO03048393A1 | Mixture of two partially denaturating agents for the preparation of pcr buffer solutions | |
US2004136979A1 | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |